- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Caris Life Sciences, Inc. Common Stock(CAI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CAI
11/13/2026: CAI (1-star) is currently NOT-A-BUY. Pass it for now.
Caris Life Sciences is a precision medicine and TechBio company specializing in molecular profiling and artificial intelligence applications for oncology. The company's primary strengths lie in its massive proprietary clinico-genomic database and comprehensive whole exome and whole transcriptome sequencing services. Its core growth story centers on expanding commercial adoption of tissue profiling and blood-based liquid biopsies alongside lucrative biopharmaceutical R&D partnerships. However, investors face notable risks including ongoing operating losses, high stock valuation sensitivity, and intense competition in molecular diagnostics. The stock is best suited for growth-oriented investors willing to tolerate high volatility while monitoring clinical execution and cash burn metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Caris exhibits rapid top-line expansion and high operating leverage within the high-growth precision oncology market. |
| Momentum investor | Strong fit while signal remains positive | The stock attracts speculative and momentum trading interest around clinical data releases and quarterly earnings beats. |
| Value investor | Weak fit | Trading at an elevated P/E multiple with ongoing profitability scaling makes it unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | The company pays no dividends, focusing instead on aggressive corporate reinvestment. |
| Low-risk investor | Weak fit | High market volatility, a high beta, and execution risks make it a poor match for conservative capital preservation. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences sharp daily and weekly price swings driven by clinical trial updates and biotech sector sentiment. |
| Valuation risk | Medium / high | Growth expectations are heavily priced in, leaving little room for operational missteps. |
| Competition risk (AI and molecular diagnostics competition) | High | Intense rivalry from well-funded peers like Guardant Health and Tempus AI threatens market share expansion. |
| Business quality | Medium | Proprietary database and unique whole-transcriptome sequencing give it a solid technological moat. |
| Dividend income | Low / none | No dividend yield is offered to investors seeking recurring cash flow. |
| Execution risk | Medium / high | Success relies heavily on scaling liquid biopsy commercialization and maintaining biopharma partnerships. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.61B USD | Price to earnings Ratio 13.88 | 1Y Target Price 34.23 |
Price to earnings Ratio 13.88 | 1Y Target Price 34.23 | ||
Volume (30-day avg) 4.1M shares | Beta - | 52 Weeks Range 14.19 - 36.50 | Updated Date 11/15/2026 |
52 Weeks Range 14.19 - 36.50 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.66 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 4.53% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Physician Services (Molecular Profiling) | Reimbursements from insurance providers, hospitals, and clinical institutions for MI Profile and genetic testing kits. | This is the core clinical diagnostic engine driving recurring day-to-day testing volume from oncologists. |
| Biopharma R&D Solutions | Data licensing agreements, target discovery fees, and clinical trial matching services provided to pharmaceutical developers. | Offers higher-margin enterprise contracts that monetize Caris's massive proprietary clinico-genomic database. |
| Geography (Domestic vs. International) | Predominantly U.S.-based clinical operations with emerging distribution partnerships spanning Asia and Europe. | The vast majority of revenue originates domestically, leaving room for international expansion over time. |
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.03 | Actual 0.05 |
Profitability
Profit Margin 9.17% | Operating Margin (TTM) 13.35% |
Management Effectiveness
Return on Assets (TTM) 7.81% | Return on Equity (TTM) 17.19% |
Valuation
Trailing PE 13.88 | Forward PE 31.55 | Enterprise Value 6.31B | Price to Sales(TTM) 6.3 |
Enterprise Value 6.31B | Price to Sales(TTM) 6.3 | ||
Enterprise Value to Revenue 6.02 | Enterprise Value to EBITDA 38.76 | Shares Outstanding 286.78M | Shares Floating 139.06M |
Shares Outstanding 286.78M | Shares Floating 139.06M | ||
Percent Insiders 48.92 | Percent Institutions 58 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

